The corticotropin releasing factor system in cancer: Expression and pathophysiological implications

Cellular and Molecular Life Sciences

Volumn 67, Issue 8, 2010, Pages 1293-1306

  Kaprara, Athina ^a   Pazaitou Panayiotou, Kalliopi ^a   Kortsaris, Alexandros ^b   Chatzaki, Ekaterini ^b  

^a Anticancer Hospital 'Theagenio'   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Cancer; Corticotropin releasing factor; Human; Urocortin receptor

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; MESSENGER RNA;

BREAST CANCER; CANCER GROWTH; CARCINOGENESIS; DIGESTIVE SYSTEM CANCER; ENDOMETRIUM CARCINOMA; HUMAN; IMMUNE SYSTEM; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTASIS; NONHUMAN; OVARY CANCER; PATHOPHYSIOLOGY; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; THYROID CANCER; TUMOR VASCULARIZATION; ANIMAL; METABOLISM; NEOPLASM; PHYSIOLOGY;

ANIMALS; CORTICOTROPIN-RELEASING HORMONE; HUMANS; NEOPLASMS;

EID: 77950602991     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-010-0265-2     Document Type: Review

References (109)

1. SpiessJ,RivierJ,RivierC,ValeW(1981)Primarystructureofcorticotropin- releasingfactorfromovinehypothalamus.ProcNatlAcadSciUSA78:6517- 6521(Pubitemid12179744)
2. Pohl S, Darlison MG, Clarke WC, Lederis K, Richter D (2001) Cloning and functional pharmacology of two corticotropinreleasing factor receptors from a teleost fish. Eur J Pharmacol 430:193-202 (Pubitemid 33050038)
3. Donaldson CJ, Sutton SW, Perrin MH, Corrigan AZ, Lewis KA, Rivier JE, Vaughan JM, Vale WW (1996) Cloning and characterization of human urocortin published erratum appears in endocrinology 1996 Sep; 137(9):3896. Endocrinology 137:2167-2170
4. Guillemin R, Rosenberg B (1955) Humoral hypothalamic control of anterior pituitary: a study with combined tissue cultures. Endocrinology 57:599-607
5. Saffran M, Schally AV (1955) The release of corticotrophin by anterior pituitary tissue in vitro. Can J Biochem Physiol 33:408-415
6. ValeW,SpiessJ,RivierC,RivierJ(1981)Characterizationofa41- residueovinehypothalamicpeptidethatstimulatessecretionofcorticotropinandbeta- endorphin.Science213:1394-1397(Pubitemid12243637)
7. TakahashiK,HaraE,SuzukiH,SasanoH,ShibaharaS(1996) ExpressionofhemeoxygenaseisozymemRNAsinthehumanbrainandinductionofhemeoxygenase- 1bynitricoxidedonors.JNeurochem67:482-489(Pubitemid26255640)
8. Vaughan J, Donaldson C, Bittencourt J, Perrin MH, Lewis K, Sutton S, Chan R, Turnbull AV, Lovejoy D, Rivier C, Rivier J, Sawchenko PE, Vale W (1995) Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropinreleasing factor see comments. Nature 378:287-292
9. Hsu SY, Hsueh AJ (2001) Human stresscopin and stresscopinrelated peptide are selective ligands for the type 2 corticotropinreleasing hormone receptor. Nat Med 7:605-611
10. Reyes TM, Lewis K, Perrin MH, Kunitake KS, Vaughan J, Arias CA, Hogenesch JB, Gulyas J, Rivier J, Vale WW, Sawchenko PE (2001) Urocortin II: A member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci USA 98:2843-2848 (Pubitemid 32209571)
11. Lewis K, Li C, Perrin MH, Blount A, Kunitake K, Donaldson C, Vaughan J, Reyes TM, Gulyas J, Fischer W, Bilezikjian L, Rivier J, Sawchenko PE, Vale WW (2001) Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci USA 98:7570-7575 (Pubitemid 32567989)
12. linoK,SasanoH,OkiY,AndohN,ShinRW,KitamotoT,TotsuneK,TakahashiK,SuzukiH, NaguraH,YoshimiT(1997) Urocortinexpressioninhumanpituitaryglandandpituitaryadenoma. JClinEndocrinolMetab82:3842-3850(Pubitemid27509381)
13. Takahashi K, Totsune K, Sone M, Murakami O, Satoh F, Arihara Z, Sasano H, Iino K, Mouri T (1998) Regional distribution of urocortin-like immunoreactivity and expression of urocortin mRNA in the human brain. Peptides 19:643-647
14. Muramatsu Y, Fukushima K, lino K, Totsune K, Takahashi K, Suzuki T, Hirasawa G, Takeyama J, Ito M, Nose M, Tashiro A, Hongo M, Oki Y, Nagura H, Sasano H (2000) Urocortin and corticotropin-releasing factor receptor expression in the human colonic mucosa. Peptides 21:1799-1809 (Pubitemid 32058855)
15. Muramatsu Y, Sugino N, Suzuki T, Totsune K, Takahashi K, Tashiro A, Hongo M, Oki Y, Sasano H (2001) Urocortin and corticotropin-releasing factor receptor expression in normal cycling human ovaries. J Clin Endocrinol Metab 86:1362-1369 (Pubitemid 32323029)
16. Kimura Y, Takahashi K, Totsune K, Muramatsu Y, Kaneko C, Darnel AD, Suzuki T, Ebina M, Nukiwa T, Sasano H (2002) Expression of urocortin and corticotropin-releasing factor receptor subtypes in the human heart. J Clin Endocrinol Metab 87:340-346 (Pubitemid 34084712)
17. Takahashi K, Totsune K, Murakami O, Saruta M, Nakabayashi M, Suzuki T, Sasano H, Shibahara S (2004) Expression of urocortin III/stresscopin in human heart and kidney. J Clin Endocrinol Metab 89:1897-1903 (Pubitemid 38507951)
18. Saruta M, Takahashi K, Suzuki T, Fukuda T, Torii A, Sasano H (2005) Urocortin 3/stresscopin in human colon: possible modulators of gastrointestinal function during stressful conditions. Peptides 26:1196-1206 (Pubitemid 40798076)
19. Florio P, Torres PB, Torricelli M, Toti P, Vale W, Petraglia F (2006) Human endometrium expresses urocortin II and III messenger RNA and peptides. Fértil Steril 86:1766-1770
20. KageyamaK,BradburyMJ,ZhaoL,BlountAL,ValeWW(1999) Urocortinmessengerribonucleicacid: tissuedistributionintheratandregulationinthymusbylipopolysaccharideandglucocort icoids.Endocrinology140:5651-5658(Pubitemid30645353)
21. Suda T, Kageyama K, Sakihara S, Nigawara T (2004) Physiological roles of urocortins, human homologues of fish urotensin I, and their receptors. Peptides 25:1689-1701 (Pubitemid 39346211)
22. Kishimoto T, Radulovic J, Radulovic M, Lin CR, Schrick C, Hooshmand F, Hermanson O, Rosenfeld MG, Spiess J (2000) Deletion of crhr2 reveals an anxiolytic role for corticotropinreleasing hormone receptor-2. Nat Genet 24:415-419 (Pubitemid 30187444)
23. Vale WW, Vaughn J, Perrin M (1997) Corticotropin-releasing factor (CRF) family of ligands and their receptors. Endocrinologist 7:3S-9S
24. Jahn O, Radulovic J, Stiedl O, Tezval H, Eckart K, Spiess J (2005) Corticotropin-releasing factor binding protein-a ligand trap? Mini Rev Med Chem 5:953-960
25. AsaSL,KovacsK,ValeW,PetruszP,VecseiP(1987) Immunohistologiclocalizationofcorticotrophin-releasinghormoneinhumantumors. AmJClinPathol87:327-333(Pubitemid17046983)
26. Fjellestad-Paulsen A, Abrahamsson PA, Bjartell A, Grino M, Grimelius L, Hedeland H, Falkmer S (1988) Carcinoma of the prostate with Cushing's syndrome. A case report with histochemical and chemical demonstration of immunoreactive corticotropin-releasing hormone in plasma and tumoral tissue. Acta Endocrinol (Copenhagen) 119:506-516
27. YamadaY,OhashiA,InoueT,SakaguchiK,TsujimuraT,OkamotoD,ItataniH,FujimotoN, KusakaK,FushimiH(2002) Cushing'ssyndromewithalargepituitaryadenomaproducingbothcorticotropin- releasinghormone(CRH)andadrenocorticotropin(ACTH).IntMed41:549- 554(Pubitemid34846255)
28. Arcuri F, Cintorino M, Florio P, Floccari F, Pergola L, Romagnoli R, Petraglia F, Tosi P, Teresa Del Vecchio M (2002) Expression of urocortin mRNA and peptide in the human prostate and in prostatic adenocarcinoma. Prostate 52:167-172 (Pubitemid 34791219)
29. Reubi JC, Waser B, Vale W, Rivier J (2003) Expression of CRF1 and CRF2 receptors in human cancers. J Clin Endocrinol Metab 88:3312-3320 (Pubitemid 36877510)
30. Tezval H, Jurk S, Atschekzei F, Serth J, Kuczyk MA, Merseburger AS (2009) The involvement of altered corticotropin releasing factor receptor 2 expression in prostate cancer due to alteration of anti-angiogenic signaling pathways. Prostate 69:443-448
31. Makrigiannakis A, Zoumakis E, Margioris AN, Theodoropoulos P, Stournaras C, Gravanis A (1995) The corticotropin-releasing hormone (CRH) in normal and tumoral epithelial cells of human endometrium. J Clin Endocrinol Metab 80:185-189
32. Graziani G, Tentori L, Portarena I, Barbarino M, Tringali G, Pozzoli G, Navarra P (2002) CRH inhibits cell growth of human endometrial adenocarcinoma cells via CRH-receptor 1-mediated activation of cAMP-PKA pathway. Endocrinology 143:807-813 (Pubitemid 34164029)
33. Graziani G, Ferrandina G, Pozzoli G, Vergati M, Muzi A, Legge F, Tentori L, Scambia G, Navarra P (2006) Corticotropinreleasing hormone receptor-1 in human endometrial cancer. Oncol Rep 15:375-379
34. Florio P, De Falco G, Leucci E, Torricelli M, Torres PB, Toti P, Dell'Anna A, Tiso E, Santopietro R, Leoncini L, Petraglia F (2006) Urocortin expression is downregulated in human endometrial carcinoma. J Endocrinol 190:99-105 (Pubitemid 44161065)
35. Miceli F, Ranelletti FO, Martinelli E, Petrillo M, Scambia G, Navarra P, Ferrandina G (2009) Expression and subcellular localization of CRH and its receptors in human endometrial cancer. Mol Cell Endocrinol 305:6-11
36. CioccaDR,PuyLA,FasoliLC,TelloO,AznarJC,GagoFE,PapaSI,SonegoR(1990) Corticotropin-releasinghormone,luteinizinghormone-releasinghormone, growthhormonereleasinghormone,andsomatostatin- likeimmunoreactivitiesinbiopsiesfrombreastcancerpatients.BreastCancerResTreat15: 175-184(Pubitemid20369897)
37. TjuvajevJ,KolesnikovY,JoshiR,SherinskiJ,KoutcherL,ZhouY,MateiC,KoutcherJ, KreekMJ,BlasbergR(1998)Anti- neoplasticpropertiesofhumancorticotropinreleasingfactor: involvementofthenitricoxidepathway.InVivo12:1-10(Pubitemid28177273)
38. Parham KL, Zervou S, Karteris E, Catalano RD, Old RW, Hillhouse EW (2004) Promoter analysis of human corticotropinreleasing factor (CRF) type 1 receptor and regulation by CRF and urocortin. Endocrinology 145:3971-3983 (Pubitemid 39037586)
39. Graziani G, Tentori L, Muzi A, Vergati M, Tringali G, Pozzoli G, Navarra P (2007) Evidence that corticotropin-releasing hormone inhibits cell growth of human breast cancer cells via the activation of CRH-R1 receptor subtype. Mol Cell Endocrinol 264:44-49 (Pubitemid 46097300)
40. Androulidaki A, Dermitzaki E, Venihaki M, Karagianni E, Rassouli O, Andreakou E, Stournaras C, Margioris AN, Tsatsanis C (2009) Corticotropin releasing factor promotes breast cancer cell motility and invasiveness. Mol Cancer 8:30
41. SudaT,TomoriN,YajimaF,OdagiriE,DemuraH,ShizumeK(1986) Characterizationofimmunoreactivecorticotropinandcorticotropin: releasingfactorinhumanadrenalandovariantumours.ActaEndocrinol(Copenhagen)111: 546-552(Pubitemid16086323)
42. ZoumakisE,ChatzakiE,CharalampopoulosI,MargiorisAN,AngelakisE, KoumantakisE,GravanisA(2001)Cycleandagerelatedchangesincorticotropin- releasinghormonelevelsinhumanendometriumandovaries.GynecolEndocrinol15: 98-102(Pubitemid32423249)
43. Minas V, Rolaki A, Kalantaridou SN, Sidiropoulos J, Mitrou S, Petsas G, Jeschke U, Paraskevaidis EA, Fountzilas G, Chrousos GP, Pavlidis N, Makrigiannakis A (2007) Intratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulation. Br J Cancer 97:637-645 (Pubitemid 47339889)
44. De Groef B, Van der Geyten S, Darras VM, Kuhn ER (2006) Role of corticotropin-releasing hormone as a thyrotropinreleasing factor in non-mammalian vertebrates. Gen Comp Endocrinol 146:62-68 (Pubitemid 43248708)
45. Birkenhager JC, Upton GV, Seldenrath HJ, Krieger DT, Tashjian AH Jr (1976) Medullary thyroid carcinoma: ectopic production of peptides with ACTH- like, corticotrophin releasing factor-like and prolactin production- stimulating activities. Acta Endocrinol (Copenhagen) 83:280-292
46. Wakabayashi I, Ihara T, Hattori M, Tonegawa Y, Shibasaki T, Hashimoto K (1985) Presence of corticotropin-releasing factorlike immunoreactivity in human tumors. Cancer 55:995-1000 (Pubitemid 15128659)
47. Delgrange E, Maker D, Donckier J, Tourniaire J (1999) Influence of age on the clinical presentation of prolactinomas in male patients. Gerontology 45:160-164 (Pubitemid 29182271)
48. ScopaCD,MastorakosG,FriedmanTC,MelachrinouM,MerinoMJ,ChrousosGP(1994) Presenceofimmunoreactivecorticotropinreleasinghormoneinthyroidlesions. AmJPathol145:1159-1167(Pubitemid24345663)
49. Tagliabue M, Pagani A, Palestini N, Manieri C, Martina V (1996) Multiple endocrine neoplasia (MEN IIB) with Cushing's syndrome due to medullary thyroid carcinoma producing corticotropin-releasing hormone. Panminerva Med 38:41-44
50. Chrisoulidou A, Pazaitou-Panayiotou K, Georgiou E, Boudina M, Kontogeorgos G, Iakovou I, Efstratiou I, Patakiouta F, Vainas I (2008) Ectopic Cushing's syndrome due to CRH secreting liver metastasis in a patient with medullary thyroid carcinoma. Hormones (Athens) 7:259-262
51. Kageyama K, Sakihara S, Yamashita M, Takahashi K, Kawashima S, Tanabe J, Tsutaya S, Yasujima M, Suda T (2008) A case of multiple endocrine neoplasia type II accompanied by thyroid medullary carcinoma and pheochromocytomas expressing corticotropin-releasing factor and urocortins. Am J Med Sci 335:398-402
52. Slominski A, Zbytek B, Zmijewski M, Slominski RM, Kauser S, Wortsman J, Tobin DJ (2006) Corticotropin releasing hormone and the skin. Front Biosci 11:2230-2248
53. Slominski A, Ermak G, Mazurkiewicz JE, Baker J, Wortsman J (1998) Characterization of corticotropin-releasing hormone (CRH) in human skin. J Clin Endocrinol Metab 83:1020-1024 (Pubitemid 28496487)
54. Fazal N, Slominski A, Choudhry MA, Wei ET, Sayeed MM (1998) Effect of CRF and related peptides on calcium signaling in human and rodent melanoma cells. FEBS Lett 435:187-190 (Pubitemid 28436580)
55. Funasaka Y, Sato H, Ichihashi M (1999) Expression of corticotropin releasing hormone in malignant melanoma. Ann N Y Acad Sci 885:391-393
56. Sato H, Nagashima Y, Chrousos GP, Ichihashi M, Funasak Y (2002) The expression of corticotropin-releasing hormone in melanoma. Pigment Cell Res 15:98-103
57. Kim MH, Cho D, Kim HJ, Chong SJ, Lee KH, Yu DS, Park CJ, Lee JY, Cho BK, Park HJ (2006) Investigation of the corticotropin-releasing hormone- proopiomelanocortin axis in various skin tumours. Br J Dermatol 155:910-915 (Pubitemid 44564498)
58. Yang Y, Park H, Yang Y, Kim TS, Bang SI, Cho D (2007) Enhancement of cell migration by corticotropin-releasing hormone through ERK1/2 pathway in murine melanoma cell line, B16F10. Exp Dermatol 16:22-27 (Pubitemid 44890347)
59. CarlsonKW,NawySS,WeiET,SadeeW,FilovVA,RezsovaVV,SlominskiA, QuillanJM(2001)Inhibitionofmousemelanomacellproliferationbycorticotropin- releasinghormoneanditsanalogs.AnticancerRes21:1173-1179(Pubitemid32494226)
60. Tsuchihashi T, Yamaguchi K, Abe K, Yanaihara N, Saito S (1992) Production of immunoreactive corticotropin-releasing hormone in various neuroendocrine tumors. Jpn J Clin Oncol 22:232-237
61. Bahro M, Pfeifer U, Dammrich J (1992) Involvement of autophagic degradation in ACTH-induced skeletal muscle atrophy. Clin Neuropathol 11:64-70
62. Auchus RJ, Mastorakos G, Friedman TC, Chrousos GP (1994) Corticotropin-releasing hormone production by a small cell carcinoma in a patient with ACTH-dependent Cushing's syndrome. J Endocrinol Invest 17:447-452
63. SudaT,TozawaF,DobashiI,HoribaN,OhmoriN,YamakadoM,YamadaM,DemuraH(1993) Corticotropin-releasinghormone,proopiomelanocortin, andglucocorticoidreceptorgeneexpressioninadrenocorticotropin- producingtumorsinvitro.JClinInvest92:2790-2795(Pubitemid24006546)
64. Calogero AE, Polosa R, Neville E, D'Agata R (1995) Measurements of hormonal peptides in the bronchoalveolar fluid as tumor markers of lung cancer. J Endocrinol Invest 18:354-358
65. Calogero AE, Minacapilli G, Nicolosi AM, Moneada ML, Mistretta A, Latteri SF, Polosa P, D'Agata R (1992) Limited clinical usefulness of plasma corticotropin-releasing hormone, adrenocorticotropin and beta-endorphin measurements as markers of lung cancer. J Endocrinol Invest 15:581-586
66. Dieterich KD, Lehnert H (2000) Decreased expression of corticotropin-releasing factor-binding protein mRNA in ACTHsecreting pituitary adenomas. Exp Clin Endocrinol Diabetes 108:59-62
67. Moody TW, Zia F, Venugopal R, Korman LY, Goldstein AL, Fagarasan M (1994) Corticotropin-releasing factor stimulates cyclic AMP, arachidonic acid release, and growth of lung cancer cells. Peptides 15:281-285 (Pubitemid 24113703)
68. Argiles JM, Figueras M, Ametller E, Fuster G, Olivan M, de Oliveira CC, Lopez-Soriano FJ, Isfort RJ, Busquets S (2008) Effects of CRF2R agonist on tumor growth and cachexia in mice implanted with Lewis lung carcinoma cells. Muscle Nerve 37:190-195 (Pubitemid 351214165)
69. Paschos KA, Charsou C, Constantinidis TC, Anagnostoulis S, Lambropoulou M, Papachristou F, Simopoulos K, Chatzaki E (2010) Corticotropin releasing hormone receptors mediate opposing effects in cholestasis-induced liver cell apoptosis. Endocrinology (in press)
70. Park SY, Rhee Y, Youn JC, Park YN, Lee S, Kim DM, Song SY, Lim SK (2007) Ectopic Cushing's syndrome due to concurrent corticotropin-releasing hormone (CRH) and adrenocorticotropic hormone (ACTH) secreted by malignant gastrinoma. Exp Clin Endocrinol Diabetes 115:13-16 (Pubitemid 46293405)
71. Simopoulos C, Christodoulou E, Lambropoulou M, Tsaroucha AK, Kakolyris S, Polychronidis A, Karayiannakis AJ, Chatzaki E (2009) Neuropeptide urocortin 1 and its receptors expressed human liver. Neuroendocrinology 89:315-326
72. Wang J, Xu Y, Xu Y, Zhu H, Zhang R, Zhang G, Li S (2008) Urocortin's inhibition of tumor growth and angiogenesis in hepatocellular carcinoma via corticotrophin-releasing factor receptor 2. Cancer Invest 26:359-368 (Pubitemid 351601386)
73. Chatzaki E, Crowe PD, Wang L, Million M, Tache Y, Grigoriadis DE (2004) CRF receptor type 1 and 2 expression and anatomical distribution in the rat colon. J Neurochem 90:309-316 (Pubitemid 38938216)
74. Kohno M, Kawahito Y, Tsubouchi Y, Hashiramoto A, Yamada R, Inoue KI, Kusaka Y, Kubo T, Elenkov IJ, Chrousos GP, Kondo M, Sano H (2001) Urocortin expression in synovium of patients with rheumatoid arthritis and osteoarthritis: relation to inflammatory activity. J Clin Endocrinol Metab 86:4344-4352 (Pubitemid 32848557)
75. Kozicz T, Arimura A (2002) Distribution of urocortin in the rat's gastrointestinal tract and its colocalization with tyrosine hydroxylase. Peptides 23:515-521 (Pubitemid 34143268)
76. Chatzaki E, Charalampopoulos I, Leontidis C, Mouzas IA, Tzardi M, Tsatsanis C, Margioris AN, Gravanis A (2003) Urocortin in human gastric mucosa: relationship to inflammatory activity. J Clin Endocrinol Metab 88:478-483 (Pubitemid 36115205)
77. ChatzakiE,MurphyBJ,WangL,MillionM,OhningGV,CrowePD,PetroskiR,TacheY, GrigoriadisDE(2004) DifferentialprofileofCRFreceptordistributionintheratstomachandduodenumassessedb ynewlydevelopedCRFreceptorantibodies.JNeurochem88:1-11(Pubitemid38030203)
78. Chatzaki E, Lambropoulou M, Constantinidis TC, Papadopoulos N, Tache Y, Minopoulos G, Grigoriadis DE (2006) Corticotropin-releasing factor (CRF) receptor type 2 in the human stomach: Protective biological role by inhibition of apoptosis. J Cell Physiol 209:905-911 (Pubitemid 44665712)
79. Lezoualc'h F, Engert S, Berning B, Behl C (2000) Corticotropin-releasing hormone-mediated neuroprotection against oxidative stress is associated with the increased release of nonamyloidogenic amyloid beta precursor protein and with the suppression of nuclear factor-kappaB. Mol Endocrinol 14:147-159
80. Karalis KP, Venihaki M, Zhao J, van Vlerken LE, Chandras C (2004) NF-kappaB participates in the corticotropin-releasing, hormone-induced regulation of the pituitary proopiomelanocortin gene. J Biol Chem 279:10837-10840 (Pubitemid 38401572)
81. Smith EM, Gregg M, Hashemi F, Schott L, Hughes TK (2006) Corticotropin Releasing Factor (CRF) activation of NF-kappaBdirected transcription in leukocytes. Cell Mol Neurobiol 26:1021-1036
82. Zhao J, Karalis KP (2002) Regulation of nuclear factor-kappaB by corticotropin-releasing hormone in mouse thymocytes. Mol Endocrinol 16:2561-2570 (Pubitemid 35266074)
83. Huang M, Kempuraj D, Papadopoulou N, Kourelis T, Donelan J, Manola A, Theoharides TC (2009) Urocortin induces interleukin-6 release from rat cardiomyocytes through p38 MAP kinase, ERK and NF-kappa B activation. J Mol Endocrinol 42:397-405
84. Yao M, Denver RJ (2007) Regulation of vertebrate corticotropin-releasing factor genes. Gen Comp Endocrinol 153:200-216 (Pubitemid 47102329)
85. Vamvakopoulos NC, Sioutopoulou TO (1994) Human corticotropin-releasing hormone receptor gene (CRHR) is located on the long arm of chromosome 17 (17ql2-qter). Chromosome Res 2:471-473
86. RossantCJ,PinnockRD,HughesJ,HallMD,McNultyS(1999)Corticotropin- releasingfactortype1andtype2alphareceptorsregulatephosphorylationofcalcium/ cyclicadenosine3′,5′-monophosphateresponseelement- bindingproteinandactivationofp42/p44mitogen-activatedproteinkinase. Endocrinology140:1525-1536(Pubitemid29149218)
87. Papadopoulou N, Chen J, Randeva HS, Levine MA, Hillhouse EW, Grammatopoulos DK (2004) Protein kinase A-induced negative regulation of the corticotropin-releasing hormone Rlalpha receptor-extracellularly regulated kinase signal transduction pathway: the critical role of Ser301 for signaling switch and selectivity. Mol Endocrinol 18:624-639 (Pubitemid 38328207)
88. Brar BK, Railson J, Stephanou A, Knight RA, Latchman DS (2002) Urocortin increases the expression of heat shock protein 90 in rat cardiac myocytes in a MEK1/2-dependent manner. J Endocrinol 172:283-293 (Pubitemid 34183077)
89. Brar BK, Jonassen AK, Stephanou A, Santilli G, Railson J, Knight RA, Yellon DM, Latchman DS (2000) Urocortin protects against ischemic and reperfusion injury via a MAPK-dependent pathway. J Biol Chem 275:8508-8514 (Pubitemid 30180198)
90. Chanalaris A, Lawrence KM, Stephanou A, Knight RD, Hsu SY, Hsueh AJ, Latchman DS (2003) Protective effects of the urocortin homologues stresscopin (SCP) and stresscopin-related peptide (SRP) against hypoxia/reoxygenation injury in rat neonatal cardiomyocytes. J Mol Cell Cardiol 35:1295-1305 (Pubitemid 37163536)
91. Punn A, Levine MA, Grammatopoulos DK (2006) Identification of signaling molecules mediating corticotropin-releasing hormone-Rlalpha-mitogen-activated protein kinase (MAPK) interactions: the critical role of phosphatidylinositol 3-kinase in regulating ERK1/2 but not p38 MAPK activation. Mol Endocrinol 20:3179-3195 (Pubitemid 44833564)
92. Chandras C, Koutmani Y, Kokkotou E, Pothoulakis C, Karalis KP (2009) Activation of phosphatidylinositol 3-kinase/protein kinase B by corticotropin-releasing factor in human monocytes. Endocrinology 150:4606-4614
93. Olianas MC, Lampis G, Onali P (1992) Human Y-79 retinoblastoma cells express functional corticotropin- releasing hormone receptors. Brain Res 593:304-306
94. Olianas MC, Lampis G, Onali P (1995) Human Y-79 retinoblastoma cells exhibit specific corticotropin-releasing hormone binding sites. J Neurochem 64:402-407
95. HaugerRL,DautzenbergFM,FlaccusA,LiepoldT,SpiessJ(1997) Regulationofcorticotropin-releasingfactorreceptorfunctioninhumanY- 79retinoblastomacells: rapidandreversiblehomologousdesensitizationbutprolongedrecovery.JNeurochem68: 2308-2316(Pubitemid27218150)
96. Gutknecht E, Hauger RL, Van der Linden I, Vauquelin G, Dautzenberg FM (2008) Expression, binding, and signaling properties of CRF2(a) receptors endogenously expressed in human retinoblastoma Y79 cells: passage-dependent regulation of functional receptors. J Neurochem 104:926-936 (Pubitemid 351143646)
97. Gutknecht E, Van der Linden I, Van Kolen K, Verhoeven KF, Vauquelin G, Dautzenberg FM (2009) Molecular mechanisms of corticotropin-releasing factor receptor-induced calcium signaling. Mol Pharmacol 75:648-657
98. Dautzenberg FM, Hauger RL (2001) G-protein-coupled receptor kinase 3- and protein kinase C-mediated desensitization of the PACAP receptor type 1 in human Y-79 retinoblastoma cells. Neuropharmacology 40:394-407
99. Radulovic M, Hippel C, Spiess J (2003) Corticotropin-releasing factor (CRF) rapidly suppresses apoptosis by acting upstream of the activation of caspases. J Neurochem 84:1074-1085 (Pubitemid 36330660)
100. Post A, Ohl F, Almeida OF, Binder EB, Rucker M, Welt S, Binder E, Holsboer F, Sillaber I (2005) Identification of molecules potentially involved in mediating the in vivo actions of the corticotropin-releasing hormone receptor 1 antagonist, NBI30775 (R121919). Psychopharmacology (Berl) 180:150-158 (Pubitemid 40897081)
101. Halasz I, Rittenhouse PA, Zorrilla EP, Redei E (1997) Sexually dimorphic effects of maternal adrenalectomy on hypothalamic corticotrophin-releasing factor, glucocorticoid receptor and anterior pituitary POMC mRNA levels in rat neonates. Brain Res Dev Brain Res 100:198-204 (Pubitemid 27286391)
102. Chatzaki E, Minas V, Zoumakis E, Makrigiannakis A (2006) CRF receptor antagonists: utility in research and clinical practice. Curr Med Chem 13:2751-2760 (Pubitemid 44509722)
103. Heinrichs SC, De Souza EB, Schulteis G, Lapsansky JL, Grigoriadis DE (2002) Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist. Neuropsychopharmacology 27:194-202 (Pubitemid 34686971)
104. Davis ME, Pemberton CJ, Yandle TG, Fisher SF, Lainchbury JG, Frampton CM, Rademaker MT, Richards M (2007) Urocortin 2 infusion in human heart failure. Eur Heart J 28:2589-2597 (Pubitemid 350071510)
105. Davis ME, Pemberton CJ, Yandle TG, Lainchbury JG, Rademaker MT, Nicholls MG, Frampton CM, Richards AM (2005) Effect of urocortin 1 infusion in humans with stable congestive cardiac failure. Clin Sci (Lond) 109:381-388
106. Wang J, Li S (2007) Corticotropin-releasing factor family and its receptors: tumor therapeutic targets? Biochem Biophys Res Commun 362:785-788
107. NishiY,TakayanagiR,YanaseT,HajiM,HasegawaY,NawataH(2000) Inhibin-likeimmunoreactivityproducedbytheadrenalglandiscirculatinginvivo. FukuokaIgakuZasshi91:8-20(Pubitemid30146041)
108. Preeyasombat C, Sirikulchayanonta V, Mahachokelertwattana P, Sriphrapradang A, Boonpucknavig S (1992) Cushing's syndrome caused by Ewing's sarcoma secreting corticotropin releasing factor-like peptide. Am J Dis Child 146:1103-1105
109. Makrigiannakis A, Margioris AN, Chatzaki E, Zoumakis E, Chrousos GP, Gravanis A (1999) The decidualizing effect of progesterone may involve direct transcriptional activation of corticotrophin-releasing hormone from human endometrial stromal cells. Mol Hum Reprod 5:789-796 (Pubitemid 29406740)